Gonadotropin-releasing hormone agonists. Current uses for these increasingly important drugs

review public-domain-us
View on PubMed
AI-generated summary by gemini-2.5-flash-lite, 2026-06-08

Gonadotropin-releasing hormone agonists transiently increase then suppress pituitary and gonadal hormones, offering reversible treatment for endometriosis, prostate cancer, and precocious puberty, with potential for broader applications.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Use of gonadotropin-releasing hormone (GnRH) agonists produces a transient increase and subsequent long-term reduction in concentrations of pituitary hormones, resulting in gonadal hormone suppression. This reversible suppression is useful in treating diseases dependent on these hormones. GnRH agonists have been approved for use in patients with endometriosis, advanced prostate cancer, and precocious puberty. As research continues, GnRH agonists are expected to change the clinical approach to the treatment of many other reproductive and nonreproductive diseases.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gonadotropin-Releasing Hormone Prostatic Neoplasms Puberty, Precocious Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Male Prostatic Neoplasms Puberty, Precocious

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-13T06:15:24.848197+00:00
pubmed
last seen: 2026-05-13T22:11:29.222973+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine